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Summary
Tuberculosis is an infectious disease caused by Mycobacterium tuberculo-
sis. The cellular immune response to mycobacteria has been characterized
extensively, but the antibody response remains underexplored. The pre-
sent study aimed to examine whether host or bacterial phospholipids
induce secretion of IgM, and specifically anti-phospholipid IgM, antibod-
ies by B cells and to identify the responsible B-cell subset. Here we show
that peritoneal B cells responded to lipid antigens by secreting IgM anti-
bodies. Specifically, stimulation with M. tuberculosis H37Rv total lipids
resulted in significant induction of total and anti-phosphatidylcholine
IgM. Similarly, IgM antibody production increased significantly with stim-
ulation by whole Mycobacterium bovis bacillus Calmette–Guerin. The B-1
subset was the dominant source of IgM antibodies after exposure to cardi-
olipin. Both CD5+ B-1a and CD5 B-1b cell subsets secreted total IgM
antibodies after exposure to M. tuberculosis H37Rv total lipids in vitro.
Overall, our results suggest that the poly-reactive B-1 cell repertoire con-
tributes to non-specific anti-phospholipid IgM antibody secretion in
response to M. tuberculosis lipids.
Keywords: activation; autoantibodies; B cells; bacterial; innate lymphoid
cells
Abbreviations: AI, acetone-insoluble; APC, allophycocyanin; AS, acetone-soluble; ASC, antibody-secreting cells; BCG, Mycobac-
terium bovis Bacillus Calmette–Guerin; CL, cardiolipin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerC, peritoneal cav-
ity; PleuC, pleural cavity; PTC, phosphatidylcholine; TB, tuberculosis
[Correction added on 11 April 2018, after first online publication: Reference 21 (Beste et al., 2005) was removed from the Reference list. All
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Introduction
According to the World Health Organization0s latest
report,1 pulmonary tuberculosis (TB) is the leading cause
of infection-induced death worldwide. Mycobacterium
tuberculosis most commonly infects the lungs and induces
a massive cellular response leading to tissue damage and
decreased respiratory function. Several challenges limit TB
diagnosis, especially in resource-constrained settings.
Prompt diagnosis with simple, rapid and inexpensive tests
is key to controlling and eliminating TB.2 Previous
attempts to develop an antibody-based test for TB diag-
nosis have failed,3,4 and the WHO has not endorsed the
use of these tests in high-prevalence settings.5
Recently, we noted a decrease in anti-phospholipid IgM
antibody levels in M. tuberculosis-infected mice following
pyrazinamide and isoniazid therapy.6 The study revealed
that anti-phosphatidylcholine and anti-cardiolipin IgM anti-
body levels decrease after anti-TB therapy. Similarly, a previ-
ous report showed a decrease in anti-phosphatidylcholine,
anti-cardiolipin, anti-phosphatidylinositol and anti-phos-
phatidylethanolamine IgM after 2 months of intense phase
anti-TB therapy in patients with non-cavitary TB.7 More-
over, Elkayam et al. reported a significant decrease in anti-
cardiolipin IgM and other autoantibodies after 6 months of
treatment.8 A better understanding of the B-cell subsets con-
tributing to this IgM pool and the regulation mechanisms
involved in IgM secretion during TB infection and disease
progression should be of relevance. Such an approach will
support the development of novel TB diagnostics that mea-
sure the induction of IgM against phospholipids.
Anti-phospholipid IgM antibodies are present in mice
without TB infection, as part of the ‘natural’ antibody reper-
toire. Natural antibodies are secreted mainly by B-1 cells,
and by B-1-derived plasma cells. B-1 cells also secrete anti-
bodies in response to bacteria-associated antigens through
T-cell-independent mechanisms.9 B-1 cell activation is regu-
lated by autocrine secretion of interleukin-10, whereas B-1
cell proliferation was shown to be induced by interleukin-
12, interleukin-5 and interferon-c, as well as pathogen-asso-
ciated molecules such as phospholipids.10 A study by Russo
and Mariano also suggested that B-1 cells migrate from the
peritoneal cavity to the lungs as part of the protective
response of mice chronically infected with Mycobacterium
bovis bacillus Calmette–Guerin (M. bovis BCG).11
Mycobacterium sp. have a thick cell wall with a high
lipid content. These lipids are released during infection
and modulate the host immune response by regulating the
secretion of pro- and anti-inflammatory cytokines.12
Whether M. tuberculosis lipids activate B-1 cells and pro-
vide the signals necessary for anti-phospholipid IgM secre-
tion remains unclear. Previous studies have shown that
the B-1 cell clonotype TEPC15 (T15) recognizes phos-
phatidylcholine (PTC) as a minimal motif prominently
expressed on oxidized, but not native, phospholipids, such
as oxidized low-density lipoprotein.13 Such oxidized phos-
pholipid antigens can be released during cell death, includ-
ing death by apoptosis. As phospholipids contain common
structural and chemical components, we hypothesized that
phospholipids derived from M. tuberculosis may play a role
in the activation of peritoneal B cells and the secretion of
IgM.
Recent evidence suggests that B-1 cells are also capable
of influencing the typical assembly of granuloma lesions
in BCG-infected lungs and of inducing host resistance to
mycobacteria.11 These findings suggest that B-1 cells may
play a protective role during chronic M. bovis infection.
However, the regulation of B-1 cell IgM antibody produc-
tion by either host or M. tuberculosis lipid antigens
remains largely unexplained. The aim of the present study
was to assess the ability of B-cell subsets to secrete IgM in
response to M. tuberculosis and host lipids.
Materials and methods
Animals
Groups of 8- to 12-week-old C57BL/6 mice were used for
the study. They were maintained at the Institute of Scien-
tific Research and High Technology Services (INDICA-
SAT-AIP). Other experiments were performed with mice
obtained from the Center for Comparative Medicine.
Animal care and handling were conducted in accordance
with Institutional Guidelines and the Animal Welfare
Committee of the University of California, Davis, CA and
INDICASAT-AIP (approval letter No. CICUA-17-001).
Pleural and peritoneal cell extraction
A pool consisting of total pleural cavity (PleuC) and peri-
toneal cavity (PerC) cells was obtained according to pre-
viously described protocols14 in order to obtain
maximum B-1 cell numbers. For the PerC lavage, we
flushed the peritoneal cavity with 10 ml of KDS-BSS
staining medium (KH-BSS potassium-HEPES buffered
salt solution supplemented with 10% Newborn Calf
Serum and 005 mM EDTA) and collected the KDS-BSS.
For the PleuC lavage, we punctured the right side of the
pleural membrane, then added 05 ml of KDS-BSS and
aspirated the fluid that contained the cells. We flushed
out the cavity twice to recover the cells. Both cell suspen-
sions were counted using a haemocytometer; dead cells
were excluded by Trypan blue staining.
B-cell subtype identification by flow cytometry
Peritoneal and pleural cells were resuspended in KDS-BSS
staining medium and blocked with anti-CD16/32. An
antibody cocktail consisting of Pacific-Blue-conjugated
antibodies was used to stain non-B cells (‘Dump’). The
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antibodies were generated in-house unless otherwise indi-
cated and included the following: anti-CD90.2, anti-CD4
(GK1.5), anti-CD8a (53-6.7), anti-Gr-1 (RB6-8c5), anti-
F4/80 (F4/80), anti-NK1.1 (PK136) and CD49b (DX-5;
BioLegend, San Diego, CA). The antibody panel used to
identify B-1 and B-2 cells included anti-CD19-Cy5-phy-
coerythrin (PE) (1D3), anti-IgM-Cy7-allophycocyanin
(APC) or anti-IgM-APC (331), anti-CD43-PE (S7) and
anti-CD23-fluorescein isothiocyanate (FITC) (B3B4.2).
For a purity check following cell separation, B-1 and B-2
cells were stained with anti-CD19-BV786 anti-IgM-
Cy7APC (331), anti-CD5-FITC, anti-CD23-APC and
Streptavidin-Qdot 605. A live–dead stain (Thermo Fischer
L34955, Rockford, IL) was used to exclude non-viable
cells. Cells were analysed using a FACS Aria flow cytome-
ter (BD Bioscience, San Jose, CA). We used different anti-
body cocktails based on surface expression markers to
delineate the B-cell subgroups. B-1 cell frequencies were
determined by gating on CD19high IgM+ IgDlow/neg
CD23neg CD43+ cells. Data were analysed using FLOWJO
software. The proliferation platform of FLOWJO was used
to assess B-cell proliferation. The Division Index is the
average number of cell divisions of all cells in a culture.
Magnetic B-cell enrichment from PleuC and PerC
B-cell suspensions from the lavage of pleural and peri-
toneal body cavities were enriched by negative selection
with a Mouse B isolation kit (R&D Systems, Inc., Min-
neapolis, MN; catalogue no.MAGM204, or Stem Cell
Technologies, Vancouver, BC, Canada, catalogue no.
19860) according to the manufacturer’s instructions. B-2
cells were excluded using an anti-CD23-biotin antibody.
Total B cells and the B-1 population were analysed by
FACS to confirm purity.
Magnetic B-cell enrichment by automated-cell separator
The biotinylated antibody cocktail described above was
added to PerC cell suspensions to exclude the ‘dump
population’. The cocktail also included anti-CD23-biotin
to exclude conventional (B-2) cells and enrich B-1. To
obtain B-2 cells from spleen, we added an anti-CD43-bio-
tin antibody followed by incubation with anti-biotin
MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Ger-
many) according to the manufacturer0s instructions.
Washed cells were passed over the column of an auto-
MACS separator (Miltenyi Biotech) as described previ-
ously.15 The purity of the recovered B cells reached at
least 90%, as determined by FACS.
B-cell sorting
Cells from the pleural and peritoneal cavities were
blocked using anti-CD16/32 (2.4G2) followed by the
addition of anti-CD19–Cy5PE (1D3), CD90.2–Pacific
blue, IgM–APC (331), IgD–Cy7PE,11–25 CD43–PE (S7),
CD5–biotin (53–7.8) and Streptavidin–Qdot 605 (Life
Technologies, Grand Island, NY). After staining, the cells
were washed with KDS-BSS staining medium followed by
addition of live/dead violet staining (Invitrogen, Carlsbad,
CA). B-cell subsets were sorted and collected in sterile
10% fetal calf serum solution in KDS-BSS by a FACS Aria
(BD Bioscience).
Mycobacterium bovis BCG culture
We used M. bovis BCG vaccine strain SSI (Statens Serum
Institute, Copenhagen, Denmark) to assess in vitro B-cell
exposure to bacteria. Mycobacterial growth was estab-
lished according to a previously established protocol.16
For the M. bovis BCG inoculum, the Mycobacterium sus-
pension was prepared to a final concentration of
80 9 103 mycobacteria/ll.
B-cell stimulation assay
Total PerC lavage, B cells, or B-1 cell suspensions at a
concentration of 1 9 106 or 2 9 105 were cultured with
or without 10 lg/ml of bovine heart cardiolipin (CL) or
PTC, lipids extracted from M. tuberculosis H37Rv or a
BCG bacteria suspension and incubated at 37° in 5%
CO2.
17 Supernatants were harvested after 1, 4 or 7 days
of culture. Total IgM and anti-phospholipid IgM secre-
tion was determined by ELISA.7
Elispot
After 3 days of incubation with CL or PTC, total IgM
antibody-secreting cells (ASCs) were enumerated by ELI-
SPOT as previously described.18 Spot counting was per-
formed with an ELISPOT reader with two fluorescent
filters, FITC and Cy3 (Autimmun Diagnostika GmbH
Strassberg, Germany). The ASCs were expressed as the
mean number of spots present in wells with countable
spot numbers.
Anti-phospholipid IgM and total IgM ELISA
To measure anti-phospholipid IgM the ELISA was
adapted from a previous report.7 A kit was used to quan-
tify total mouse IgM (Mouse IgM Ready-SET-Go! eBio-
science, SanDiego, CA) following the protocol given by
the manufacturer.
B-1 cell proliferation assay
PerC B-1 cells enriched via AutoMACS were used in a
proliferation assay using a protocol modified from
Nguyen et al.19 Briefly, B-1 cells at a concentration of 107
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cells/ml were labelled with efluor 670 dye. After the efluor
incubation, the cells were cultured for 3 days with or
without 10 lg/ml of M. tuberculosis lipids in a 5% CO2
environment. Viability stain was added and purity evalua-
tion was performed with the following antibody cocktail:
anti-CD19-BV786, anti-IgM-Cy7APC (331), anti-CD5–
FITC, anti-CD23-APC and streptavidin–Qdot 605. FACS
analysis was used to determine the number of cell divi-
sions after lipid stimulation.
B-1 cell and B-1 subset differentiation assay
PerC B-1 cells were enriched using FACS Aria, and
CD138 flow cytometry assessment was performed accord-
ing to a previously described protocol.15 Briefly, B-1 cells
were stained as outlined above and B-1a and B-1b cells
were sorted on a FACSAria into the following groups:
Live, Dump, CD19+, IgM+, IgDlow/negative, CD23 and
CD5+ or CD5. Cells were plated at 1 9 105 cells/well
with or without M. tuberculosis H37Rv total lipid extract
(20 µg/ml) and cultured for 3 days. Cells were re-stained
using the following panel: Live, Dump, CD19+, IgM+,
IgDlow/negative, CD23, CD5+ and CD138+, and analysed
on an LSR Fortessa (BD), or plated for ELISPOT assay.
Culture supernatants were assessed for IgM using ELISA.
Statistical analysis
GRAPHPAD PRISM software (version 60) was used to anal-
yse the data. One-way or two-way analysis of variance
followed by Bonferroni’s test was used for multiple com-
parisons between experimental groups. Changes in IgM
antibody levels were considered statistically significant at
*P < 001, **P < 0001 and ***P < 00001. The unpaired
Student’s t-test was used for statistical analyses when
comparing non-stimulated and stimulated cells. The sig-
nificant results are shown as *P < 005.
Results
Peritoneal cavity cells respond to cardiolipin and
phosphatidylcholine
The secretion of IgM antibodies by B-1 cells in response
to antigens and pathogens other than M. tuberculosis has
been detected in mice previously.20 In order to determine
the role of PerC B-1 cells in the anti-phospholipid IgM
antibody response, we stimulated total PerC cells with CL
or PTC (both isolated from bovine heart) and measured
the levels of anti-CL and anti-PTC IgM antibodies after
1, 4 and 7 days of treatment (Fig. 1). We observed signif-
icantly higher levels of anti-CL IgM on day 7 of culture
when PerC cells were stimulated with CL and PTC com-
pared with controls (Fig. 1a and d). In contrast, although
we observed significantly higher levels of specific anti-
PTC IgM after 4 and 7 days of PTC stimulation (Fig. 1b)
we did not find differences in the levels of non-specific or
cross-reactive anti-PTC antibodies in response to CL
(Fig. 1c). These results indicate that total PerC cells pro-
duced specific anti-phospholipid IgM antibodies in
response to lipid antigens and suggested that in our
experimental model, PTC stimulates anti-phospholipid
IgM secretion more efficiently than CL.
B cells from peritoneal cavity secrete IgM antibodies
in response to M. tuberculosis H37Rv lipids and
M. bovis BCG
To determine the capacity of B cells to produce IgM anti-
bodies in response to mycobacterial lipids, we measured
IgM levels in cultures of purified PerC B cells stimulated
with M. tuberculosis H37Rv total lipid fraction, acetone-
soluble (AS) or acetone-insoluble (AI) lipid fractions. The
M. tuberculosis H37Rv total lipids activated the secretion
of total IgM antibody in cultures of B cells stimulated
with this lipid fraction; total IgM antibody levels were
significantly higher for stimulated B cells compared with
those of non-stimulated controls (80 ng/ml versus
4716 ng/ml, P = <00001) (Fig. 2a). B cells stimulated
with the M. tuberculosis H37Rv AS or AI lipid fractions
produced significantly higher levels of anti-CL IgM anti-
bodies compared with non-stimulated control cells
(250 ng/ml and 239 ng/ml versus. 82 ng/ml, both at
P < 005) (Fig. 2b). Finally, significantly higher levels of
anti-PTC IgM antibodies were also secreted in response
to M. tuberculosis H37Rv total lipids, the AS lipid frac-
tion, and the AI lipid fraction stimuli when compared
with non-exposed controls (255 ng/ml, P < 0005;
250 ng/ml P < 00005; 239 ng/ml, P < 0005; 234 ng/
ml, P < 0005; respectively) (Fig. 2c).
To further demonstrate the ability of PerC B cells to
secrete IgM antibodies in response to whole live bacteria,
we exposed the cells to M. bovis BCG at a ratio of 25 : 1
(25 bacteria to one B cell).21 We noted a significant
increase in total IgM in response to M. bovis BCG stimu-
lation (80 ng/ml versus 2450 ng/ml, P = 0003)
(Fig. 2a). Moreover, we found significantly higher anti-
PTC IgM levels in cultures with bacteria compared with
non-exposed controls (306 ng/ml versus 87 ng/ml,
P = 0009) (Fig. 2c). The results demonstrate that B cells
from PerC secrete IgM antibodies in response to a com-
plex mixture of lipid antigens derived from M. tuberculo-
sis H37Rv and to whole live M. bovis BCG.
Peritoneal cavity B-1 cells respond more strongly to
phospholipid stimulation than B-2 cells
B-1 cells play a role in the host immune response as nat-
ural antibody producers.22 It is well known that B-1 cells
respond to innate antigen signals, including pathogen-
ª 2018 John Wiley & Sons Ltd, Immunology, 154, 613–623616
C. Ordo~nez et al.
associated molecules such as lipopolysaccharide.23,24 Our
previous results showed that PerC B cells are involved in
IgM antibody secretion in response to phospholipid anti-
gens. Therefore, we decided to determine which B-cell
subset contributed to IgM secretion (total, anti-CL and
anti-PTC) after phospholipid stimulation.
To make this determination, cells were stained and live,
‘non-dump’ CD19+ IgM+ B cells were separated into B-1
(CD23 CD43+) and B-2 (CD23+ CD43) cells by FACS,
as outlined in Fig. 3(a). Purified cells were cultured with or
without CL or PTC, and IgM ASCs were enumerated by
ELISPOT 3 days after culture onset. The results showed that
a higher frequency of stimulation-induced IgM production
was present among B-1 cells compared with B-2 cells
(Fig. 3b and c). Stimulation with PTC did not induce signif-
icant increases in IgM ASC of either subset.
Notably, B-2 IgM ASCs showed a non-significant
response after stimulation with CL, whereas B-1 cells
responded strongly (126 9 103  374 spots, Fig. 3c). In
addition to ASC frequency changes, stimulation with CL
and PTC increased the average ELISPOT size, suggesting
increased production of IgM per B-1 cell compared with
non-stimulated cultures (data not shown). The above
findings corroborate previous results indicating that B-1
cells secrete IgM antibodies in response to various phos-
pholipid stimuli.
Proliferation of pleural and peritoneal B-1 cells after
M. tuberculosis H37Rv lipid stimulation
Lipopolysaccharide-activated B-1 cells are known to pro-
liferate strongly before differentiation into ASCs.23
Among B-2 cells, the response is strongest from marginal
zone B cells.25 To further test whether M. tuberculosis
H37Rv lipids could directly stimulate B-1 cells to prolifer-
ate and differentiate into ASC, we performed proliferation
assays. B-1 cells were purified from PerC cells by mag-
netic separation and stained with e-fluor-APC. Loss of
dye indicates B-cell proliferation. The data show that
M. tuberculosis H37Rv lipid stimulation induced a small
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Figure 1. Peritoneal cavity (PerC) cells respond to bovine heart phospholipid antigens. Total PerC cells from C57BL/6 mice were plated at
1 9 106 cells per well and then cultured with or without 10 µg/ml of cardiolipin (CL) or phosphatidylcholine (PTC) isolated from bovine heart.
The graph shows specific anti-CL and anti-PTC IgM antibodies secreted after stimulation with CL and PTC, respectively (a, b); and the cross-
reactive anti-PTC and anti-CL IgM antibodies secreted after stimulation with CL and PTC respectively (c, d). Antibody levels were measured after
1, 4 and 7 days of stimulation by in-house ELISA. Results are shown as means  SD of two independent experiments (n = 9). Significance was
determined at *P < 001 and ***P < 00001 compared with non-stimulated cells.
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but significant increase in B-1 cell proliferation compared
with cultures without stimulation, with significant
increases in the number of cells that divided and the
average number of divisions that these cells underwent
(Fig. 4a and b). Together, our results suggest that B-1
cells undergo significant minimal proliferation in
response to M. tuberculosis H37Rv lipid stimulation.
B-1 cells and their B-1a subset strongly respond to
M. tuberculosis H37Rv total lipids
To characterize the differentiation into ASCs, we isolated
B-1 cells from PerC by negative enrichment, using auto-
MACS, and then evaluated the expression of the CD138
surface marker as well as IgM secretion after stimulation
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Figure 2. B cells from the peritoneal cavity secrete IgM antibodies against Mycobacterium lipids. B cells from the peritoneal cavity (PerC) of
C57BL/6 mice were collected and cultured with or without 20 µg/ml of total cell wall lipids, acetone-soluble (AS) and acetone-insoluble (AI)
lipid fractions from Mycobacterium tuberculosis H37Rv cell wall, as well as whole bacilli Mycobacterium bovis bacillus Calmette–Guerin (BCG) at a
ratio of 25 : 1 (M. bovis BCG : B cell). The supernatants were harvested after 4 days of stimulation and total IgM (a), anti-cardiolipin (CL) IgM
(b), and anti- phosphatidylcholine (PTC) IgM (c) antibodies were measured by an in-house ELISA. Results are shown as means  SD (n = 6).
*P < 001, **P < 0001 and ***P < 00001 compared with non-stimulated controls.
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with M. tuberculosis H37Rv total lipids. We observed a
significantly higher proportion of CD138-positive B-1
plasma cells after stimulation with M. tuberculosis H37Rv
lipids (average of 87% and 11%, respectively, P = 0001;
Fig. 5a). Importantly, we also found increases in B-1 cell
IgM ASCs after stimulation with M. tuberculosis H37Rv
total lipids, whereas B-2 showed no significant increases
(Fig. 5b, left panel). This was consistent with the concen-
trations of IgM detected in the supernatants of these cul-
tures, with B-1 cell cultures having significantly higher
IgM concentrations than B-2 cells (626 ng/ml versus
73 ng/ml, respectively, P = 00006) (Fig. 5b, right panel)
in response to M. tuberculosis H37Rv total lipid stimula-
tion. Taken together, all the above results indicate that B-
1 cells produce IgM antibodies not only in response to
phospholipid stimuli but also in response to M. tubercu-
losis total lipids.
To determine further which subset of B-1 cells is
responsive to M. tuberculosis H37Rv lipids, we performed
FACS-purification of B-1a and B-1b and then stimulated
the cells with M. tuberculosis H37Rv total lipid extract for
3 days. FACS contour plots showed a higher proportion
of B-1a cells differentiated to express the plasma cell mar-
ker CD138+ compared with B-1b cells (320% and 140%,
respectively, P = 00005; Fig.5c). Consistent with these
changes, the addition of lipid extract increased the pro-
portion of B-1a IgM ASCs to a larger extent than that of
B-1b (160% and 96%, respectively, P = 004; Fig. 5d,
left panel). The concentrations of IgM in the supernatants
of B-1a cultures were about fivefold higher compared
with those of the B-1b cultures (1908 ng/ml and
350 ng/ml, P = 0007; Fig. 5d right panel). Hence, both
B-1a and B-1b cells responded to M. tuberculosis lipids
with increased IgM secretion; however, B-1a seemed to
respond more strongly. Overall, the data indicate a higher
differentiation rate of B-1a cells into total IgM-secreting
plasma cells after stimulation with M. tuberculosis H37Rv
lipids.
Discussion
This study aimed to evaluate the role of B-cell subsets in
the humoral immune response to mammalian and
mycobacterial phospholipids. We demonstrate that B-1
cell subsets, mainly B-1a, are major responders to in vitro
stimulation with various phospholipids, including those
from Mycobacterium. The stimulation led to only weak
proliferation of purified B-1 cells, but strong and rapid
differentiation of those cells into CD138+ IgM-secreting
plasma cells.
B-1 cell activation and the subsequent production of
IgM antibody in response to foreign antigens or patho-
gens are essential to the innate host defence. There is
increasing evidence that B-1 cells secrete antibodies natu-
rally and in response to infection-induced processes.26 B-
1 cells have the capacity to recognize self-antigens and
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Figure 4. B-1 proliferation in response to stimulation with Mycobacterium tuberculosis total lipids. Peritoneal cavity cells from C57BL/6 mice were
collected and B-1 cells enriched by magnetic cell separation and labelled with e-Fluor dye. Cells were cultured with or without 20 µg/ml of total
M. tuberculosis lipid extract for 3 days and cell proliferation rates were determined by flow cytometry. Histograms demonstrate loss of e-fluor
staining, indicative of proliferation (a). Survival rates of stimulated cells (b, left plot). Average number of divisions per cell expressed as division
index (b, middle plot). Mean frequencies  SD of B-1 cells that did divide (b, right plot). Results are representative of two experiments with sim-
ilar results. Significance was determined as **P < 0001 and ***P < 00001 compared with non-stimulated cells.
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microbial antigens; this may be due to cross-reactivity
between self and foreign antigens. Our results show both
specific and cross-reactive IgM responses to phospho-
lipids. We observed that PerC cells produced anti-CL and
anti-PTC IgM in response to stimulation with CL and
PTC, respectively, but these cells also secreted anti-CL
IgM in response to PTC stimulation. Our findings suggest
that IgM antibodies secreted by PerC B cells exhibit
cross-reactivity between PTC and CL. A study on human
haemolytic anaemia has described similar cross-reactivity
between CL-binding and PTC-binding antibodies.27 These
authors proposed that the polar head present in all lipid
structures is the region recognized by IgM antibodies. We
believe that the B-1 ASCs are secreting non-specific
polyreactive antibodies rather than specific antibodies to
PTC and CL. What stimulates the B-1 cells to secrete
polyreactive natural antibodies during M. tuberculosis
infection in the susceptible host remains unknown.
To stimulate B cells with mycobacterial lipids, we used
the total lipid mixture extract from M. tuberculosis
H37Rv, as well as the AI and AS fractions provided by
BEI Resources. The lipid content of these fractions has
been described elsewhere.28 The AI lipid fraction was
noted to be rich in glycolipids and phospholipids, which
are associated with the M. tuberculosis cell envelope and
interactions with the immune cell response.29 The AS
lipid fraction, on the other hand, is composed of mycolic
acid species with methyl esters. In addition, this fraction
includes mono- and diglycerides, cholesterol, triglycerides
and non-polar glycopeptidolipids. We identified the
secretion of IgM antibodies, including anti-PTC and anti-
CL, in response to both AS and AI lipid fractions. We
hypothesize that phospholipids present in the mycobacte-
rial cell envelope, including both the outer and inner
membrane, may induce B-cell activation and IgM secre-
tion during Mycobacterium infection of a vertebrate host.
We noted higher total IgM secretion in response to the
entire M. tuberculosis lipids mixture and whole bacteria
M. bovis BCG compared with stimulation with the AI or
AS fraction alone. A plausible explanation is that the total
lipid fraction, as well as the whole bacteria, contain a
wide array of lipids with higher immunogenic properties
than AS and AI lipid fraction stimuli. However, the secre-
tion of anti-CL and anti-PTC IgM antibodies after
mycobacterial lipid stimulation suggest that a portion of
the IgM antibodies produced by PerC B cells lacks speci-
ficity.
The secretion of anti-phospholipid IgM antibodies
facilitates tissue healing during tuberculosis treatment and
clearance. These antibodies have been reported to bind
apoptotic cells and facilitate the clearance of dead cells
and debris. Specifically, anti-phospholipid IgM antibodies
enhance procoagulant activity and the uptake and clear-
ance of apoptotic cells.30 These essential steps are
required to eliminate cell debris resulting from inflamma-
tion and tissue damage during M. tuberculosis infection.
Hence, natural antibodies might function to restore
homeostasis and promote recovery in the lungs. Other
studies suggested, however, that antibodies can have a
deleterious effect on cell-mediated immune responses. For
example, anti-M. tuberculosis glycolipid IgM antibodies
have been associated with a diminished cell-mediated
immune response to tuberculin antigens.31 Also, high
levels of IgG anti-tuberculin antibodies decrease the T-cell
response in high-risk individuals with latent TB infec-
tion.32 Consequently, vaccine development efforts avoid
inducing a strong antibody response to mycobacterial
lipid antigens.
Anti-phospholipid IgM levels during TB are directly
related to the bacterial burden within the lungs. We pre-
viously observed that TB patients without lung cavities
and undergoing 2 months of anti-TB therapy decreased
their blood anti-phospholipid IgM antibody levels.7,8 Sim-
ilar changes were observed in M. tuberculosis-infected
mice following pyrazinamide and isoniazid therapy.6 This
study revealed that anti-PTC and anti-CL IgM antibody
levels also decrease after anti-TB therapy in mice.
Recently, we analysed IgM antibodies in pleural lavage of
mice after local infection with M. bovis BCG.33 In this
study, we found that the levels of total and anti-PTC IgM
antibodies rise with infection and remain detectable
90 days post infection with BCG, whereas anti-cardiolipin
IgM antibody levels decreased with bacteria clearance.
The present study provides in vitro evidence that the B-1
cell population contributes to in vivo IgM production
when exposed to M. tuberculosis lipids and whole BCG
bacterium. Animal TB infection models and clinical stud-
ies are now warranted to explore the molecular
Figure 5. B-1a and B-1b cells differentiate in response to Mycobacterium tuberculosis H37Rv total lipids to IgM-secreting plasma cells. (a–d) Mag-
netic bead-enriched B-1 cells from peritoneal cavity (PerC) and pleural cavity (PleuC) were cultured with or without 20 lg/ml of M. tuberculosis
lipids. The percentage of cell division cycles was determined by flow cytometry analysis. The proportion B-1 cell differentiation was determined
by the expression of CD138 (a). Proportion of B-1 or B-2 IgM antibody-secreting cells (ASCs) and total IgM secretion after stimulation with
M. tuberculosis H37Rv total lipid extract (b). IgM ASCs were enumerated by ELISPOT after overnight culture. FACS contour plot with outliers
showing CD138 expression among B-1a and B-1b cells before and after stimulation with M. tuberculosis H37Rv total lipid extract. Right plot
indicates the mean  SD of all cultures (c). Mean  SD of B-1a and B-1b IgM secreters as assessed by ELISPOT (left) and mean  SD IgM in
supernatants of cultures with or without stimulation with M. tuberculosis H37Rv total lipid extract (d). Results were considered statistically signif-
icant at *P < 005. Results are one representative of two independent experiments that gave similar results.
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mechanisms and kinetics of IgM antibody production fol-
lowing TB infection. Such an effort will contribute to the
understanding of anti-phospholipid IgM antibodies as a
potential biomarker for monitoring anti-TB therapy, pre-
dicting disease progression and vaccine development.
Such in vivo studies could also describe the response and
dynamics of the B-1 cell repertoire during both TB and
latent TB infection.
The detection of IgM, IgG and IgA antibody subclasses
in response to M. tuberculosis antigens indicates early
signs of antigenic stimulation as well as the infection
and progression stages in TB patients.34 Recently, serum
testing for Mycobacterium leprae infection demonstrated
a significant relationship between the levels of anti-phe-
nolic glycolipid-I (anti-PGL-1) IgM antibodies and clini-
cal improvement after therapy.35 We previously reported
a decrease in anti-phospholipid IgM antibodies after
2 months of intense phase anti-TB therapy in patients
with non-cavitary TB disease.7 Hence, therapeutic follow
up that includes testing for anti-CL or anti-PTC IgM
antibodies might be a suitable method for monitoring
TB therapy regimens in non-cavitary TB patients or for
predicting disease progression. For now, our study pro-
vides evidence of the ex vivo secretion of IgM by B-1
cells in response to various lipids, including those
derived from M. tuberculosis and whole bacterium
M. bovis BCG.
The details of B-cell and IgM antibody dynamics dur-
ing TB, anti-TB therapy and vaccination in humans
remain unclear. A recent study found distinct B-cell sub-
populations in peripheral blood during active TB disease
and other lung disease conditions.36 Although Plessis
et al. looked at IgM+-activated B-cell subpopulations,
they failed to identify the B-1 cell subpopulation among
their patient cohort. Hence, the proportions of this cell
subset found in healthy individuals versus patients with
TB or other lung diseases are not known. On the other
hand, Russo and Mariano suggested that B-1 cells migrate
from the peritoneum to mycobacterial pulmonary lesions
in mice.11 Their study did not investigate the mechanisms
of B-1 cell activation. We believe that delineating the acti-
vation mechanisms of these B-1 cells and their subsets in
TB patients would greatly strengthen our understanding
of this cell subset’s contribution to physiopathology and
disease control. Further clinical studies looking at the
specific B-cell subpopulations will help us to clarify both
questions.
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